ALSYMPCA trial: Ra-223 effective and well-tolerated for CRPC with symptomatic bone metastases
ALSYMPCA trial: Ra-223 effective and well-tolerated for CRPC with symptomatic bone metastases
Predictive power of PSA patterns during off-time treatment periods with intermittent androgen deprivation
Enzalutamide improves survival in men with metastatic castration-resistant prostate cancer
MET variant as a prognostic marker in clear cell renal cell carcinoma
Results of orteronel plus prednisone in the TAK-700 trial on mCRPC
Results of the MARS study in renal cell carcinoma
Dissecting the biology of the androgen receptor pathway
IBM Watson for Healthcare
The future of ontology
W3C and semantic web tecnology
Improving research capabilities with semantic web technology
W3C and maintaining the semantic web platform